Details of the Drug

General Information of Drug (ID: DM6HDKQ)

• Drug Name: [3H]mibolerone
• Synonyms: Mibolerone; MIBOLERONE; 3704/9/4; Miboleronum; Mibolerona; Cheque; U-10,997; UNII-9OGY4BOR8D; NSC 72260; 9OGY4BOR8D; U 10997; Matenon; Miboleron; 17-beta-Hydroxy-7-alpha,17-dimethylestr-4-en-3-one; CHEBI:34849; U-10997; 17beta-Hydroxy-7alpha,17-dimethylestr-4-en-3-one; (7alpha,17beta)-17-hydroxy-7,17-dimethylestr-4-en-3-one; 7alpha-17alpha-dimethyl-19-nortestosterone; CDB 904; Cheque (Veterinary)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 302.5
  Logarithm of the Partition Coefficient (xlogp); 3.2
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 2
• Chemical Identifiers:
  Formula: C20H30O2
  IUPAC Name: (7R,8R,9S,10R,13S,14S,17S)-17-hydroxy-7,13,17-trimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
  Canonical SMILES: C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C)O
  InChI: InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1
  InChIKey: PTQMMNYJKCSPET-OMHQDGTGSA-N
• Cross-matching ID:
  PubChem CID: 251636
  ChEBI ID: CHEBI:34849
  CAS Number: 3704-09-4
  TTD ID: D06VZE

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Inhibitor	[2]
Androgen receptor messenger RNA (AR mRNA)	TTKPW01	ANDR_HUMAN	Agonist	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acireductone dioxygenase (ADI1)	OT8IOD03	MTND_HUMAN	Gene/Protein Processing	[4]
Homeobox protein Nkx-3.1 (NKX3-1)	OT0DO6ZU	NKX31_HUMAN	Gene/Protein Processing	[5]
Kallikrein-2 (KLK2)	OT9RE37R	KLK2_HUMAN	Gene/Protein Processing	[6]
Matrilysin (MMP7)	OTVT3SEJ	MMP7_HUMAN	Gene/Protein Processing	[7]
Prostate-specific antigen (KLK3)	OTFGSBFJ	KLK3_HUMAN	Gene/Protein Processing	[6]
Vascular endothelial growth factor A, long form	OTIM9MZ3	VEGFA_HUMAN	Gene/Protein Processing	[8]

Molecular Expression Atlas of This Drug

• The Studied Disease: Discovery agent
• ICD Disease Classification: N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Androgen receptor (AR)	DTT	AR	2.13E-01	-0.07	-0.11

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3456).
• [2] Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile... J Med Chem. 2000 Aug 24;43(17):3344-7.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
• [4] Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. Neoplasia. 2007 Aug;9(8):643-51. doi: 10.1593/neo.07415.
• [5] A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology. 1999 Nov;140(11):5451-4. doi: 10.1210/endo.140.11.7246.
• [6] Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999 Dec 1;59(23):5892-5.
• [7] Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J Biol Chem. 1996 Sep 27;271(39):23907-13. doi: 10.1074/jbc.271.39.23907.
• [8] Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells. Toxicology. 2015 Jul 3;333:45-52. doi: 10.1016/j.tox.2015.04.002. Epub 2015 Apr 3.